← All earnings call summaries
Kwality Pharmaceuticals Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Oncology revenue expected INR100-110 crores in FY27; expansion adds 45-50% capacity
- Biosimilar revenue target INR600-700 crores by FY29; Keytruda launch expected end CY28
- Capex INR185-195 crores planned over FY27-FY29; funded by internal accruals
- FY27 revenue guidance INR700+ crores; EBITDA margin 26-27%
- EBITDA margin expected to reach ~30% by FY29 with revenue growth to INR1000 crores
- Hormone plant commercializing Nov 2026; INR70-80 crores revenue in FY28, INR150-200 crores in FY29
- FY30 revenue target INR1300-1500 crores; 35-40% generics, 25% oncology, 15-20% hormone, 15-30% biosimilars
- Working capital improving; debtor days expected to reduce to 165-170 days
- Multiple registrations quarterly; 6-7 new product registrations expected Q2 FY27 onwards
- KPMG auditor appointment planned by Q3/Q4 FY27
📄 Source: View original transcript (PDF)
Get Kwality Pharmaceuticals Limited earnings summaries on Telegram
Add Kwality Pharmaceuticals Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.